TELCON RF PHARMACEUTICAL. Statistics

Total Valuation

TELCON RF PHARMACEUTICAL. has a market cap or net worth of KRW 56.58 billion. The enterprise value is 93.34 billion.

Market Cap	56.58B
Enterprise Value	93.34B

Important Dates

The next estimated earnings date is Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	n/a

Share Statistics

TELCON RF PHARMACEUTICAL. has 12.03 million shares outstanding. The number of shares has decreased by -17.91% in one year.

Current Share Class	n/a
Shares Outstanding	12.03M
Shares Change (YoY)	-17.91%
Shares Change (QoQ)	+3.00%
Owned by Insiders (%)	0.00%
Owned by Institutions (%)	0.45%
Float	9.19M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.48
PB Ratio	0.59
P/TBV Ratio	0.75
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-9.29
EV / Sales	2.53
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-35.06

Financial Position

The company has a current ratio of 0.31, with a Debt / Equity ratio of 0.45.

Current Ratio	0.31
Quick Ratio	0.17
Debt / Equity	0.45
Debt / EBITDA	11.67
Debt / FCF	-16.12
Interest Coverage	-0.31

Financial Efficiency

Return on equity (ROE) is -10.43% and return on invested capital (ROIC) is -0.34%.

Return on Equity (ROE)	-10.43%
Return on Assets (ROA)	-0.32%
Return on Capital (ROIC)	-0.34%
Revenue Per Employee	290.96M
Profits Per Employee	-79.12M
Employee Count	127
Asset Turnover	0.26
Inventory Turnover	5.01

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -42.82% in the last 52 weeks. The beta is 0.12, so TELCON RF PHARMACEUTICAL.'s price volatility has been lower than the market average.

Beta (5Y)	0.12
52-Week Price Change	-42.82%
50-Day Moving Average	5,534.40
200-Day Moving Average	6,781.30
Relative Strength Index (RSI)	29.80
Average Volume (20 Days)	41,704

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TELCON RF PHARMACEUTICAL. had revenue of KRW 36.95 billion and -10.05 billion in losses. Loss per share was -862.34.

Revenue	36.95B
Gross Profit	9.08B
Operating Income	-708.58M
Pretax Income	-10.09B
Net Income	-10.05B
EBITDA	3.68B
EBIT	-708.58M
Loss Per Share	-862.34

Full Income Statement

Balance Sheet

The company has 6.45 billion in cash and 42.90 billion in debt, giving a net cash position of -36.46 billion or -3,031.74 per share.

Cash & Cash Equivalents	6.45B
Total Debt	42.90B
Net Cash	-36.46B
Net Cash Per Share	-3,031.74
Equity (Book Value)	95.53B
Book Value Per Share	7,918.47
Working Capital	-38.92B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.69 billion and capital expenditures -4.35 billion, giving a free cash flow of -2.66 billion.

Operating Cash Flow	1.69B
Capital Expenditures	-4.35B
Free Cash Flow	-2.66B
FCF Per Share	-221.40

Full Cash Flow Statement

Margins

Gross margin is 24.56%, with operating and profit margins of -1.92% and -27.19%.

Gross Margin	24.56%
Operating Margin	-1.92%
Pretax Margin	-27.30%
Profit Margin	-27.19%
EBITDA Margin	9.95%
EBIT Margin	-1.92%
FCF Margin	n/a

Dividends & Yields

TELCON RF PHARMACEUTICAL. does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	17.91%
Shareholder Yield	17.91%
Earnings Yield	-18.33%
FCF Yield	-4.71%

Stock Splits

The last stock split was on December 10, 2024. It was a reverse split with a ratio of 0.1.

Last Split Date	Dec 10, 2024
Split Type	Reverse
Split Ratio	0.1

Scores

TELCON RF PHARMACEUTICAL. has an Altman Z-Score of -0.68. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.68
Piotroski F-Score	n/a